Navigation Links
Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy

In a first ever study conducted to by researchers at Columbia University Medical Center to analyze the link between colon cancer death rates and adherence to cancer treatment, //it has been found that nearly one third of the patients had stopped their chemotherapy. More specifically, stage III colon cancer patients who were prescribed a combination of leucovorin and 5-fluorouracil for 6 months, were found to stop their treatment before completion.

Non-compliance rates in this were as high as 30%. Although previous studies have shown that not adhering to the chemotherapy regimen is associated with shorter survival rates. Moreover, it equates to being offered no treatment at all. Despite this fact, colon cancer patients fail to take the issue seriously. The researchers have therefore urged all colon cancer patients to complete their chemotherapy regime, to reap the maximum benefit of the cancer treatment.

‘The intuitive thinking is that if you complete most of a treatment regimen, you should get most of the treatment benefit. But these findings are significant because they indicate that completing treatment is as critical for colon cancer as it is for breast cancer – and we need to do better to ensure that patients who can, complete treatment as intended,’ said Alfred I. Neugut, M.D., Ph.D., who led the study along with Dawn L. Hershman, M.D., M.S.

The study will be published in the May 20, 2006 issue of the Journal of Clinical Oncology (published online April 17, 2006).

The research team used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify stage III colon cancer patients who were at least 65 years of age or older, and who received one to seven months of fluorouracil (FU)-based adjuvant chemotherapy treatment.

Among the 1,579 patients who survived eight months or longer, the 1,091 (69.1 percent) who underwent five to seven months of treatment survived nearly twice as long as the 488 (30.9 percent) who received only one to four months of treatment. Patients, who were older, unmarried and had comorbid conditions, were more likely to receive less than five months of treatment.

The same research team recently published (Journal of Clinical Oncology, Sept. 20, 2005 issue) the first study to link treatment completion issues with race and poor survival rates. The 2005 study found that black women with early stage breast cancer were more likely than their counterparts of other races to abandon chemotherapy before completing their full course of treatment. The findings shed new light on why breast black cancer patients experience lower survival rates than other women, despite a lower incidence.

Source: Eurekalert

Related medicine news :

1. Cancers of Colon & Rectum linked to Cigarette Smoking
2. Need for Colon cancer screening
3. Beer guards against Colon Cancer
4. Important substance in curry conciliate Inflamed Colon
5. Colon cancer linked with common virus
6. Colon cancer risk linked to genes causing Hemochromatosis
7. Death Risk Higher in Obese Women with Colon Cancer
8. Inflammation Linked to Colon Cancer
9. Aspirin Found To Reduce The Risk Of Colon Cancer
10. Blood Marker Found To Predict Colon Cancer
11. Estrogen Found To Protect the Colon Against Cancer
Post Your Comments:

(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today ... Meeting. Their Ecosystem empowers dentists to make complex business decisions by providing the tools ... receive a free fee survey with 10 procedures customized by zip code. , ...
(Date:11/30/2015)... Grove, IL (PRWEB) , ... November 30, 2015 , ... ... for an emerging pharmaceutical company. Because it is so important to this key industry ... “Success Factors in your IND Filing” on December 4th at 11am EST. , Federal ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... has verified that their Vasont Universal Integrator (VUI) extension unites with Syncro Soft’s ... and managing content as a continuous process with the latest release of oXygen® ...
(Date:11/30/2015)... California (PRWEB) , ... November 30, 2015 , ... ... a strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue ... synthetic polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support ...
(Date:11/30/2015)... ... 2015 , ... Healthjump, Inc. announced that it has acquired ... development and support company. The purchase will expand the capability to serve clients ... the services currently provided by Healthjump. , Through this purchase, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Wash. , Nov. 30, 2015  Precision ... Post-Processing services, is pleased to announce a dramatic ... medical imaging services. Building on its ISO-9001:2008 certification ... and implemented comprehensive Core Lab protocols and procedures. ... variety of research activities.  Their Core Lab services ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare ... and Life Sciences Report 2015 . --> Pharmaboardroom releases ... . Latin America , a country of ... , a country of over 122 million people. --> ... healthcare, pharmaceuticals, or life sciences insights into the second largest pharma ...
Breaking Medicine Technology: